Purpose: STAT3 is known to have both oncogenic and tumor suppressive effects, but the regulation of these opposing effects is elusive. We hypothesized that STAT3b, one of the two STAT3 isoforms, is the key determinant in this context.
Introduction
Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family of transcription factors, is responsible for the signal transduction of a host of extracellular stimuli, such as the IL6 family cytokines and various growth factors (1) (2) (3) . Upon these stimulations, phosphorylation of STAT3 Y705 is essential for the subsequent dimerization, nuclear translocation, and activation of STAT3 (1) (2) (3) . The oncogenic potential of STAT3 has been well documented; specifically, the constitutively activated STAT3 mutant (commonly labeled STAT3C) can effectively induce malignant transformation (4) , and many human cancers harbor constitutively active STAT3 (1) (2) (3) . Nevertheless, accumulating evidence from both experimental and clinical studies has suggested that STAT3 may also carry a tumor suppressor role in specific contexts (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . For instance, in a mouse model of intestine adenoma, tissue-specific STAT3 gene knockout was found to enhance tumor invasion and promote tumor progression (5, 6) . STAT3 expression was found to be reduced in the majority of skin squamous cell carcinomas compared with adjacent nonmalignant tissues (8) . Moreover, nuclear-STAT3 or pSTAT3 Y705 was shown to correlate with a better prognosis in multiple cancers, such as head and neck squamous cell carcinoma, salivary gland cancer, low-grade or node-negative breast cancer, colorectal cancer, and nasopharyngeal carcinoma (9) (10) (11) (12) (13) (14) . In a recent review article, we have speculated that the molecular basis of how STAT3 can function as a tumor suppressor and oncoprotein may be related to the existence of two STAT3 isoforms, STAT3a and STAT3b (3). STAT3b, a truncated form of the full-length STAT3a, is generated by alternative splicing of exon 23 (15) (16) (17) . The cis-regulatory elements in the STAT3 gene that are responsible for the generation of STAT3b have been identified (18) , and the STAT3b 3 0 acceptor site was found to be located 50 nucleotides downstream of the STAT3a 3 0 acceptor site in exon 23, which corresponds with the alternative splicing site that generates the STAT3b isoform (15) (16) (17) . STAT3b is identical to STAT3a with the exception of 55 amino acids at the C-terminal of STAT3a that are replaced by a unique 7-amino-acid sequence of STAT3b (15) (16) (17) . Importantly, in comparison with STAT3a, STAT3b lacks the C-terminal transcription activation domain. A relatively small number of previous publications have suggested that STAT3b is a tumor suppressor (19) (20) (21) (22) (23) . For instance, it has been reported that STAT3b induces cell-cycle arrest and apoptosis in melanoma cells (19) (20) (21) (22) . A study published in 1996 using COS-1 cells (a monkey kidney cell line) suggested that the tumor suppressor effects of STAT3b may be related to its heterodimerization with STAT3a, thereby inhibiting the transactivation activity of STAT3a (16) . Nonetheless, the biologic and clinical significance of STAT3b in human cancers has not been extensively examined. Whether STAT3b can indeed inhibit STAT3a in human cancer cells has not been extensively examined or established. We believe that virtually all previously published clinical studies examining the prognostic significance of STAT3 in cancers did not examine the relative expression and contributions of the two STAT3 isoforms separately.
Esophageal squamous cell carcinoma (ESCC) is one of the most deadly cancers worldwide, representing the fifth leading cause of cancer-related death in male and the eighth in female (24) . Aberrant activation of STAT3 has been shown to promote tumorigenesis in this type of cancer (25) (26) (27) (28) . Using ESCC as a study model, we examined the interaction between STAT3a and STAT3b in details, with the hope that the generated data can provide insights into the tumor suppressor role of STAT3b and the molecular mechanism underlying the dual role of STAT3 in cancers. Our data show that STAT3b is a key regulator of the signaling and oncogenic effects of STAT3a. Our findings support the concept that the relative expression levels of STAT3a and STAT3b as well as their interactions dictate whether STAT3 is tumor suppressive or oncogenic in a specific setting.
Materials and Methods

Patient samples
Human ESCC tumors and adjacent nontumorous esophageal epithelial tissues were collected directly after surgical resection between October 2007 and July 2009, at the Department of Tumor Surgery of Shantou Central Hospital (Shantou, China). The cases were selected based on a clear pathologic diagnosis, follow-up data, and had not received local or systemic treatment before surgery. The frozen tissues, including both the case-paired adjacent noncancerous esophageal epithelial tissues and the tumor samples that were used for the Western blot analysis, were rigorously resected by pathologists to ensure that only the epithelium of the normal esophagus was included in the noncancerous tissues, and that no benign tissues were included in tumor samples. The histologic characterization and clinicopathologic staging of the samples were performed in accordance with the 7th edition of American Joint Committee on Cancer Tumor-NodesMetastasis staging system. Detailed clinical information of the patients with ESCC is described in Supplementary Table S1 . The study was approved by the ethical committee of the Central Hospital of Shantou City and the ethical committee of Shantou University Medical College, and written informed consent was obtained from all surgical patients to use resected samples for research.
Cell lines and stable cell cone generation
Human ESCC cell line EC109 was obtained from the Chinese Academy of Medical Sciences, Beijing, China. KYSE150 cell line was kindly provided by Dr. Ming-Zhou Guo, Chinese PLA General Hospital, Beijing, China. Both cell lines have been authenticated using short tandem repeat DNA profiling. The generation of the STAT3b and STAT3C Tetracycline-off stable cell clones was performed according to the protocol provided by the manufacturer of the Tetracycline-off system (Clontech). Briefly, EC109 and KYSE150 cells were first transfected with the pTet-Off vector that expresses tetracycline-controlled transactivator, and stable cell clones were selected by exposure to 400 mg/mL geneticin (Invitrogen). Then, these stable clones were transfected with the pTRE2hyg-STAT3b or pTRE2hyg-STAT3C vectors, and double stable cell clones were selected using media containing 400 mg/mL hygromycin B (Invitrogen). EC109 and KYSE150 cells were cultured in DMEM and RPMI-1640 medium supplemented with 10% FBS, respectively.
Animal study
Note that 1 Â 10 6 KYSE150-TetOff-STAT3b cells pretreated with/without 100 ng/mL doxycycline (Dox) were injected subcutaneously into the flank of male nude mice that were 8 weeks
Translational Relevance
The oncogenic function of STAT3 has been revealed in various cancers. However, recent studies have revealed a tumor suppressor role of STAT3 in multiple cancer types. In esophageal squamous cell carcinoma (ESCC), we revealed a mechanism that may explain the opposing roles of STAT3 in cancer. We found that although STAT3b (a truncated isoform of STAT3) attenuated STAT3 transcription activity, suppressed the cancer stem cell population, and sensitized ESCC cells to chemotherapy in vivo, it substantially increased the Tyrosine 705 -phosphorylation, nuclear translocation, and DNA binding/ promoter occupation of STAT3a (the full-length and oncogenic isoform of STAT3). In support of these findings, high STAT3b expression converts the prognostic value of pSTAT3a
Y705 from unfavorable to favorable in patients with ESCC. These findings suggest that whether STAT3 is oncogenic or tumor suppressive is largely dictated by STAT3b, which carries important implications as to how the biologic and prognostic significance of STAT3 in cancers should be interpreted. were detected by IHC using antibodies against Flag (Sigma; F3165) and phospho-STAT3a Y705 (Cell Signaling; #9145), respectively.
Chromatin immunoprecipitation coupled to detection by PCR (ChIP-PCR)
The EZ-ChIP kit (Millipore) was used for this assay, and the experiments were performed according to the manufacturer's instructions. Briefly, 48 hours after the transfection of wild-type STAT3b-Flag, mutant STAT3b-Y705F-Flag, or empty vector into the EC109 cells, 1 Â 10 7 cells were treated with 1% formaldehyde to cross-link proteins to DNA, and the cell lysates were sonicated to shear the DNA into lengths between 200 and 1,000 bp. The sheared DNA fragments were immunoprecipitated with antibodies against STAT3a (Cell Signaling, 1:50), Flag (Sigma, 1:50), or mouse IgG provided by the ChIP kit. The primers used for the PCR amplification of the PLK1 promoter region containing the STAT3 binding sites were: Primer 1, forward:
Flow cytometry analysis Cell apoptosis was determined by the propidium iodide and Annexin V double staining assay. Briefly, cells were gently dissociated with trypsin and stained with propidium iodide and Annexin V using the Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences) according to the manufacturer's instructions. For side population cell identification, a previously described method was used (26) . For CD44 detection, cells were gently dissociated with trypsin and stained with APC-conjugated CD44 antibody (BD pharmingen, 1:25) or the Mouse IgG2b, k isotype control antibody (BD pharmingen, 1:25), and flow cytometry analysis was performed. All the flow cytometry data were analyzed using the Flow Jo software.
Statistical analysis
The statistical analyses were performed using either the SPSS V.13.0 statistical software package or the Graphpad Prism6. To determine the differences between two independent groups of samples, Student t test was used. Survival curves were plotted using the Kaplan-Meier method and compared using the logrank test. The x 2 test or Fisher exact test was used to analyze the correlation between the expression of STAT3b and pSTAT3a Y705 , and the association of the expression status of various STAT3 markers and the clinical-pathologic parameters. Differences were considered significant when the P value was less than 0.05.
Other Materials and Methods can be found in Supplementary Data.
Results
High STAT3b expression correlates with a favorable prognosis in patients with ESCC
To our knowledge, the prognostic significance of STAT3b in human cancers has never been assessed. Using IHC and a STAT3b-specific monoclonal antibody (29), we surveyed STAT3b expression in a cohort of 286 ESCC tumors. As shown in Fig. 1A , 28 (9.8%) tumors expressed high levels of STAT3b, whereas 128 (44.8%) and 130 (45.5%) tumors expressed negative/weak and moderate STAT3b levels, respectively (Fig. 1B) . Benign epithelia adjacent to the tumors strongly expressed STAT3b in the suprabasal layer but negative in the basal layer (Fig. 1A) . Kaplan-Meier analysis revealed that moderate/strong expression of STAT3b significantly correlated with a longer overall survival (P ¼ 0.0009) and recurrence-free survival (P ¼ 0.0001; Fig. 1C ). Moreover, among the 95 patients with ESCC who received radio-chemotherapy, patients with tumors expressing moderate/strong STAT3b had a significantly longer overall survival (P ¼ 0.005) and recurrence-free survival (P ¼ 0.006), as compared with those with tumors expressing negative/weak levels of STAT3b (Fig. 1C) . Furthermore, as shown in Supplementary Table S2 , tumors with moderate/strong STAT3b expression were significantly less likely to have lymph node metastasis (P < 0.001) and correlated with a low clinical stage (P < 0.001). Multivariate Cox regression analysis revealed that moderate/strong expression of STAT3b is a significant independent protective factor for both overall survival [HR ¼ 0.711, 95% confidence interval (CI) ¼ 0.511-0.990, P ¼ 0.043] and recurrence-free survival (HR ¼ 0.708, 95% CI ¼ 0.515-0.974, P ¼ 0.034; Fig. 1D ).
STAT3b decreases the cancer stem cell population and sensitizes ESCC cells to chemotherapy in vitro
The prognostic significance of STAT3b suggests that STAT3b is a tumor suppressor in ESCC. To delineate the mechanism, we employed EC109 and KYSE150 cells that had been stably transfected with STAT3b cloned in a conditional expression vector (i.e., the tetracycline-off system), and these cells were labeled EC109-STAT3b-TetOff and KYSE150-STAT3b-TetOff, respectively. As shown in Fig. 2A and Supplementary Fig. S1A and S1B, enforced expression of STAT3b (i.e., no doxycycline treatment) in EC109 cells significantly decreased the clonogenic capacity and increased their sensitivity to 5-FU and cisplatin in a STAT3b dose-dependent manner (P < 0.05). Similar observations were made with KYSE150-STAT3b-TetOff cells (Supplementary Fig. S1C ). To determine whether the tumor suppressor function of STAT3b was mediated via antagonizing the oncogenic function of STAT3a, the relative expression of STAT3a and STAT3b were modulated using STAT3 siRNA and doxycycline, respectively, in the same two cell lines. As shown in STAT3b suppresses the chemoresistance and stem-like properties of ESCC cells. A, doxycycline (Dox) was used to control STAT3b expression in EC109-STAT3b-TetOff cells. B, the function of STAT3b in chemoresistance was determined using clonogenic assay, and the correlation between STAT3b and chemoresistance was analyzed (Pearson correlation). C and D, protein expression was determined by Western blots, and chemoresistance was assessed using clonogenic assay and Propidium iodide and Annexin V double staining. EC109-STAT3b-TetOff cells were used in the experiments shown in panel D. E, tumorsphere formation assay was performed using EC109-STAT3b-TetOff cells. Scale bars, 50 mm. F, Hoechst 33342 dye efflux assay and CD44 staining were performed using EC109-STAT3b-TetOff cells. Gray graph indicates negative control. G, top, a diagram showing the experimental design of the animal study, in which KYSE150-STAT3b-TetOff cells were used as a cell model. Bottom, the tumor volume changes relative to the initial tumor volume before drug treatment are plotted (n ¼ 8 in each group), and representative tumors are shown. H, H&E staining and IHC were performed in mice xenografts. Scale bars, 50 mm. All the data are presented as the mean AE SD, Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001, Student t test.
expression of STAT3b (i.e., no doxycycline treatment) dramatically decreased the clonogenic ability and markedly enhanced the chemosensitivity of ESCC cells to 5-FU and cisplatin, which was comparable to the effects of STAT3a knockdown. Because extensive studies have linked cancer stem cells to chemoresistance (30), we therefore determined the impact of STAT3b on the cancer stem cell population of ESCC cells. As shown in Fig. 2E , cells with enforced expression of STAT3b (no doxycycline treatment) or STAT3a knockdown formed approximately 2-fold less tumorspheres compared with the negative controls (P < 0.01). Furthermore, the number of cells per tumorsphere was significantly decreased ($3.5-fold) in response to either treatment (P < 0.001; Fig. 2E ). To directly quantify cancer stem cells, we performed Hoechst and CD44 staining, as reported in previous studies (26, 31) . As shown in Fig. 2F , enforced expression of STAT3b and STAT3a knockdown significantly decreased the Hoechst-negative cancer stem cells from 1.12% to 0.46% and 0.63%, respectively. Similarly, CD44
high cancer stem cells were also decreased by enforced expression of STAT3b and STAT3a knockdown, from 19.2% to 12.3% and 11.6%, respectively (Fig. 2F ). Similar observations were made in KYSE150-STAT3b-TetOff cells ( Supplementary  Fig. S2B ).
STAT3b sensitizes ESCC cells to chemotherapy in vivo
The tumor suppressor function of STAT3b was further tested in nude mice xenografted with KYSE150-STAT3b-TetOff cells. As illustrated in Fig. 2G , xenograft formation was detectable consistently on day 8, after which multiple doses of 5-FU or cisplatin was injected into these animals intraperitoneally. We observed significant differences in tumor growth rate between animals that received doxycycline (i.e., low level of STAT3b) and those did not (i.e., high level of STAT3b) from day 14 for 5-FU and day 17 for cisplatin ( Fig. 2G) . Under both chemotherapy regimens, xenografts with high STAT3b expression shrank significantly faster than those with low STAT3b expression (P < 0.05; Fig. 2G ). The histologic features and the expression status of STAT3b (detectable by FLAG antibody) in these xenografts are shown in Fig. 2H .
STAT3b enhances the Tyrosine705 phosphorylation and nuclear translocation of STAT3a, which is dependent on the Tyrosine705 residue in STAT3b
Despite the potent tumor suppressor function of STAT3b as shown above, we observed that enforced expression of STAT3b (controlled by doxycycline) substantially increased pSTAT3a Y705 both in vitro ( Fig. 2A and C and Supplementary Fig. S1C ) and in vivo (Fig. 2H) . To further validate these findings, wild-type STAT3b cDNA, mutant STAT3b Y705F cDNA, and STAT3 siRNAs were transiently transfected into EC109 and KYSE150 cells to manipulate the relative expression of STAT3a and STAT3b. Consistently, we found that STAT3b transfection again increased pSTAT3a Y705 levels (Fig. 3A) , and both enforced expression of STAT3b and STAT3a knockdown significantly decreased the chemoresistance and the clonogenic ability in both the cell lines (P < 0.01; Fig. 3A and Supplementary Fig. S3 ). However, Y705F mutation in STAT3b significantly abrogated its tumor suppressor effect (P < 0.05). These findings suggest that the tumor suppressor effects of STAT3b may be related to its interaction with STAT3a, and Tyrosine705 is an important residue for the function of STAT3b.
Thus, we examined the interplay between these two isoforms closely. As shown in Fig. 3B, enforced signal in STAT3b-transfected cells was maintained at a high level for at least 120 minutes after OSM stimulation. This effect of STAT3b was found to be dependent on its Tyrosine705 residue, as replacement by phenylalanine at this site almost completely abrogated the observed effects (Fig. 3B) .
Further studies using the subcellular fractionation experiment showed that the high level of pSTAT3a Y705 induced by STAT3b was evenly distributed between the cytoplasm and nucleus (Fig.  3C) . Furthermore, even in the absence of OSM stimulation, STAT3b transfection led to a substantial increase in the expression of pSTAT3a Y705 in ESCC cells, and the STAT3b-induced pSTAT3a Y705 was again evenly distributed between the cytoplasm and nucleus (Fig. 3C) . Results from confocal microscopy analysis were in line with these interpretations (Fig. 3D) .
Finally, in support that the enhancing effect of STAT3b on pSTAT3a Y705 also occurs in patient samples, Western blot studies revealed a significant correlation between STAT3b and pSTAT3a Y705 expression in our cohort of ESCC samples (n ¼ 91, P ¼ 0.019; Fig. 3E and Supplementary Fig. S4 ).
STAT3b protects pSTAT3a Y705 from dephosphorylation by protein tyrosine phosphatases (PTP)
The molecular mechanism underlying the enhancing effect of STAT3b on the expression of pSTAT3a Y705 remains unclear. We hypothesized that STAT3b could interfere with the interaction between PTPs and STAT3a. To this end, we selected PTP-MEG2, a recently identified PTP that specifically interact with STAT3 to dephosphorylate pSTAT3 Y705 in breast cancer cells (32) . As shown in Fig. 4A , compared with empty vector transfection, STAT3b dramatically decreased the interaction between STAT3a and PTP-MEG2, whereas Y705F mutation of STAT3b diminished the effect exerted by STAT3b. Results obtained from the confocal microscopy studies are in keeping with our model (Fig. 4B) . Specifically, co-localization between STAT3a and PTP-MEG2 was observed in empty vector transfected cells, whereas this interaction was abolished in STAT3b transfected cells. In comparison, transfection of the STAT3b Y705F mutant was not able to reduce this co-localization (Fig. 4B) .
STAT3b enhances the DNA binding of STAT3a by forming heterodimers, whereas the transcriptional activity of STAT3a was decreased by STAT3b
The tumor suppressor role of STAT3b and the enhancing effect of STAT3b on the oncogenic pSTAT3a Y705 prompted us to determine how STAT3b influences the function of STAT3a in ESCC cells. First, reciprocal co-immunoprecipitation experiment showed that STAT3b was able to form heterodimers with STAT3a, and this interaction was enhanced by OSM stimulation (Fig. 5A) . In comparison, the functional defective STAT3b Y705F mutant could not effectively form heterodimers with STAT3a (Fig. 5A) , suggesting that the heterodimerization is required for the function of STAT3b. We then validated this finding using confocal microscopy (Fig. 5B) . Specifically, upon OSM stimulation, transfected STAT3b translocated to the nuclei and overlapped with the nuclear-STAT3a, whereas the STAT3b Y705F mutant was largely localized in the cytoplasm and showed no substantial co-localization with STAT3a. We then assessed how STAT3b affects the transcriptional activity of STAT3a. A STAT3 reporter was used, and luciferase activity served as the readout. Because STAT3a but not STAT3b carries the domain responsible for transcription regulation, the luciferase activity detectable should reflect the transcription activity of STAT3a alone. As shown in Fig. 5C and Supplementary Fig. S5 , Figure 3 . STAT3b enhances the Tyrosine705 phosphorylation and nuclear translocation of STAT3a, which is dependent on the Tyrosine705 residue in STAT3b. A, protein expression in the transfected cells was detected using Western blots, and chemoresistance was measured using clonogenic assay. B, protein expression was measured using Western blots in cells treated with OSM for different times. C, the cytoplasmic and nuclear expression of STAT3a and STAT3b. D, confocal microscopic detection of pSTAT3 Y705 in the transfected EC109 cells. Scale bars, 10 mm. E, correlation between STAT3b and pSTAT3a Y705 in ESCC samples (n ¼ 91).
Details are described in Supplementary Fig. S4 . phosphorylation, it dramatically decreased the transcriptional activity of STAT3 as compared with negative control (P < 0.001). Again, the Y705F mutation significantly diminished the effect of STAT3b (P < 0.01). Similar results were observed when these two cell lines were stimulated with OSM ( Fig. 5C and Supplementary Fig. S5 ). To further validate these observations, we repeated the same experiments using EC109-STAT3C-TetOff cells. As shown in Fig. 5C , doxycycline treatment effectively suppressed STAT3C expression and decreased the STAT3 transcriptional activity by approximately 40% (P < 0.01). In comparison, although transfection of STAT3b increased pSTAT3a Y705 , the STAT3 transcriptional activity was decreased by >80% (P < 0.001).
We then asked whether the decreased STAT3 transcriptional activity induced by STAT3b was caused by a reduction in STAT3 DNA-binding ability. A pull-down experiment using a probe that contains the STAT3 consensus DNA-binding site was performed. Surprisingly, we found that STAT3b markedly promoted the DNAbinding of STAT3a, compared with the negative control and STAT3b Y705F (Fig. 5D) . Moreover, STAT3b was also able to effectively bind to the DNA probe. To determine whether STAT3b can enhance the occupancy of STAT3a in the promoter region of its downstream target genes, ChIP-PCR was performed. PLK1, a reported oncogenic mediator of STAT3 in ESCC (25) , was selected for this experiment. As shown in Fig. 5E , we found that transfection of wild-type STAT3b but not the mutant STAT3b Y705F markedly increased the occupancy of both STAT3a and STAT3b (FLAG-tagged) in the PLK1 promoter. However, enforced expression of STAT3b dramatically decreased the expression of PLK1 to an extent that was comparable to STAT3a knockdown in both parental and STAT3b-TetOff cells (Fig. 5F ). Again, Y705F mutation in STAT3b abrogated its function in suppressing PLK1 expression (Fig. 5F ). Taken together, these data indicate that the transcriptional activity of STAT3a was decreased by STAT3b, although the DNA binding of STAT3a was enhanced by STAT3b via forming heterodimers.
STAT3b determines the prognostic significance of pSTAT3a
Y705 in patients with ESCC
Our collected data indicates that STAT3b inhibits the transcriptional activity and oncogenic function of STAT3a, although it "paradoxically"' increases the level of pSTAT3a Y705 . Thus, a high level of pSTAT3a Y705 indicates a tumor suppressive environment when STAT3b is expressed, whereas it indicates an oncogenic environment when STAT3b is negative/weak. Using Western blots, we assessed the relative expressions of STAT3a and STAT3b in 91 frozen tumors, which overlapped with the initial cohort of 286 cases mentioned above ( Fig. 6A and Supplementary Fig. S4 ). Case-matched, benign esophageal tissues adjacent to the tumors were included for comparison. We also included the fascin expression levels, as fascin is known to be frequently overexpressed in ESCC (33) . In seven pairs of the randomly chosen samples from our cohort, six tumors showed a dramatic increase in fascin expression compared with the case-matched benign tissues, supporting the validity of our paired ESCC samples in this cohort (Fig. 6A ). As shown in Fig. 6B , the expression of STAT3b significantly correlated with the STAT3b immunoreactivity illustrated in Fig. 1 (P ¼ 0.0001) , supporting the validity of our methodology. Results of the expression status of STAT3a and STAT3b, as well as their phosphorylated forms, are summarized in Fig. 6B .
In support of our model, a high level of pSTAT3a Y705 significantly correlated with a longer overall survival in patients with STAT3b-high tumors (n ¼ 45, P ¼ 0.039; Fig. 6C ). In STAT3b-low tumors (n ¼ 46), although pSTAT3a Y705 did not significantly correlate with the overall survival (P ¼ 0.802; Fig. 6C ), we noted Figure 5 . STAT3b enhances the DNA binding of STAT3a by forming heterodimers, whereas the transcriptional activity of STAT3a was decreased by STAT3b. A, reciprocal co-IP was performed to assess the interaction between STAT3a and STAT3b. B, confocal microscopy was performed to evaluate the co-localization of STAT3b and STAT3a in transfected EC109 cells treated with 10 ng/mL OSM for 30 minutes. Scale bars, 10 mm. C, STAT3 luciferase reporter activity was measured 48 hours after transfection, and Western blot was performed in parallel.
ÃÃ , P < 0.01; ÃÃÃ , P < 0.001, Student t test. D, 30 minutes after OSM (10 ng/mL) treatment, the STAT3 DNA-binding ability was determined using a pull-down assay with a STAT3 probe. E, ChIP-PCR was performed to determine the occupancy of STAT3a/b in the promoter of PLK1 in EC109 cells. F, protein expression was detected using Western blots. and STAT3a/b in 7/91 pairs of samples (T, tumor; N, adjacent nontumorous tissue). The complete data and details are described in Supplementary Fig. S4 . B, left, STAT3b expression detected by Western blot correlated with STAT3b immunoreactivity illustrated in Fig. 1 Fig. 6C ). Finally, in this entire group of 91 patients, pSTAT3a
Y705 level showed a trend toward a better outcome (P ¼ 0.082; Fig. 6E ), which can be attributed to the paradoxical enhancing effect of STAT3b on the oncogenic pSTAT3a Y705 .
Discussion
One of the key findings of this study is that STAT3b is a tumor suppressor in ESCC, as evidenced by the observation that enforced expression of STAT3b in ESCC cells significantly reduced colony formation, increased chemosensitivity, and suppressed cancer stem cell populations. Importantly, we have delineated the key mechanisms underlying the tumor suppressor effects of STAT3b, especially in the aspects of how STAT3b interacts with STAT3a biochemically and functionally. Our data support the hypothetical model illustrated in Fig. 6E . Specifically, upon cytokine (e.g., OSM) stimulation, at least two types of STAT3 dimers are formed, that is, pSTAT3a:pSTAT3a homodimer and pSTAT3a:pSTAT3b heterodimer. Compared with the pSTAT3a:pSTAT3a homodimer, the pSTAT3a:pSTAT3b heterodimer is theoretically more stable due to the absence of the negatively charged C-terminal region in STAT3b, which has been shown to increase the stability of STAT3b homodimers (17, 34) . Because only monomerized pSTAT3a can be subjected to dephosphorylation by PTPs (17) , the stabilizing effect of STAT3b on the STAT3a:STAT3b heterodimer blocks the interaction and dephosphorylation by PTPs. Thus, a much larger amount of pSTAT3 (as heterodimers) is preserved, which is distributed in both the cytoplasm and the nucleus. Nevertheless, the oncogenic function of the transcriptionally active pSTAT3a is sequestered in this large pool of pSTAT3 heterodimers that are still capable of binding DNA. Therefore, in the presence of sufficient STAT3b, STAT3a signaling is retarded, although the amount of pSTAT3 Y705 is markedly increased by STAT3b. In comparison, in tumors in which STAT3b is downregulated, although pSTAT3 Y705 expression is relatively less, the transcriptionally active and oncogenic STAT3a are relatively unchecked. In other words, whether STAT3 is oncogenic or tumor suppressive is largely dictated by the expression status of STAT3b.
The tumor suppressor function of STAT3b has not been extensively studied or published. In addition to its dominant negative effect on STAT3a, it is believed that STAT3b also may regulate the expression of a unique gene set (15, 23, 35, 36) . Nonetheless, the mechanism underlying tumor suppressor effects of STAT3b is not completely understood, and the concept is challenging, because at least two studies have shown that STAT3b promotes leukemogenesis and the progression of liver cancer (37, 38) . Regarding the evidence supporting the tumor suppressive effects of STAT3b, we have identified only 11 studies in the literature that have discussed about this subject to varying extents. In 7 of these 11 studies, the STAT3b construct was only used as an experimental tool to block STAT3a, believed to act in a dominant negative fashion (21, 22, (39) (40) (41) (42) (43) . In the remaining four studies, the main objective was to evaluate how effective STAT3b is as a tumor suppressor (19, 20, 23, 44) . Notably, only one of these studies demonstrates that STAT3b directly decreases the transcriptional activity of STAT3a (41) . Besides these 11 studies in cancer cells, we are aware of 3 other studies that had evaluated the impact of STAT3b on the transcriptional activity of STAT3a in COS cells: one of these studies revealed that STAT3b significantly decreased the transcriptional activity of STAT3a (16) , whereas two other studies described that STAT3b could increase the transcriptional activity of STAT3a (15, 17) .
Although our data strongly support that STAT3b is a tumor suppressor in ESCC, we found that this isoform paradoxically increases STAT3a Y705 phosphorylation. A similar finding has been reported in one study using murine embryonic fibroblasts (35), but our present study is the first to address this phenomenon in cancer cells and to delineate the underlying mechanisms (Fig.  6E) . Importantly, our findings may explain the accumulating controversies regarding the tumor suppressor function of STAT3 in various cancer types (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . For instance, there are many publications in which the immune-detection of pSTAT3 Y705 or nuclear STAT3 was found to significantly correlate with a better outcome (9) (10) (11) (12) (13) (14) . The explanations for these seemingly discrepant results have not been satisfactory or proven. In our recent review of STAT3 in cancer, we have discussed about the hypothesis that the expression status of STAT3b in cancer cells is a key determinant of the exact biologic effects of STAT3 (3). Thus, in STAT3b-negative/ weak tumors, activation of STAT3 increases pSTAT3a Y705 , which exerts potent oncogenic effects. In contrast, in STAT3b-high tumors, although pSTAT3a Y705 is dramatically augmented by STAT3b, the overall oncogenic effects of STAT3 are indeed suppressed by STAT3b. In other words, without the distinction between the two STAT3 isoforms, as in the case of virtually all previously published clinicopathologic studies of STAT3, it is perceivable that one may conclude that a high expression level of pSTAT3a Y705 or total pSTAT3 Y705 is oncogenic if the vast majority of the tumors in the study cohort are STAT3b-negative/weak. Alternatively, one may conclude that pSTAT3a Y705 or total pSTAT3 Y705 is tumor suppressive or carries no significance if a substantial proportion of the tumors in the study cohort are STAT3b-high. In support of this model, in our current study, in which 55.2% (158/286) of the tumors carried a relatively high level of STAT3b (i.e., moderate/strong STAT3b staining) as assessed by IHC, pSTAT3a Y705 correlated with longer survival (Fig. 6D) . Thus, in the presence of high STAT3b expression, the amount of pSTAT3 Y705 likely reflects the stabilizing effects of STAT3b on pSTAT3a Y705 , rather than an authentic indicator of the transcriptionally active and oncogenic pSTAT3a Y705 ; and prognostic value of STAT3 in cancer can be fully assessed only if expression status of both STAT3a and STAT3b is known.
Although our data show that the Y705 residue is important for STAT3b in attenuating the biologic function of STAT3a, the STAT3b Y705F mutant could still decrease the transcription activity of STAT3a (Fig. 5C ). This observation can be attributed to its dominant negative effect on STAT3a, which is similar to the mechanism reported for the dominant negative STAT3a Y705F mutant (45) . Specifically, like the STAT3a Y705F mutant, the intact SH2 domain in STAT3b Y705F can compete with STAT3a for the binding to the tyrosine phospho-peptides on gp130, thereby hampering the phosphorylation and activation of STAT3a Y705 by JAKs. In support of this hypothesis, our data show that transfection of the STAT3b Y705F mutant appreciably decreased the expression of pSTAT3a Y705 (Fig. 5C ), which may explain the decrease of STAT3a transcription activity by this STAT3b mutant.
STAT3 has been shown to regulate cancer cell stemness in several types of cancers, including breast cancer, glioblastoma, and ESCC (3, 26) . For instance, in ESCC, the JAK2/STAT3 pathway was shown to increase the side population cells and CD44 High cells (26) , two subsets of ESCC cells that have been demonstrated to have cancer stem cell features (26, 31) . Our study is the first to show that STAT3b suppresses cancer stemness, as evidenced by the decrease of both side population cells and CD44
High cells. This finding is expected, as our data show that STAT3b suppresses the transcription activity and antagonizes the oncogenic function of STAT3a in the ESCC model. Recently, a study reported that morpholinos, a type of artificial small molecules, was able to modulate the STAT3 alternative splicing process to favor the generation of STAT3b at the expense of STAT3a (23) . Given that STAT3b opposes the oncogenic role of STAT3a in cancer stemness, these small molecules can be potentially used as a powerful tool to target cancer stem cells.
In conclusion, we have presented data supporting that STAT3b is a tumor suppressor in ESCC, and STAT3b can effectively suppress the oncogenic effects of STAT3a. Our results support the model that STAT3 can be both oncogenic and tumor suppressive, and the expression status of STAT3b is the key regulator of this dual role. Our study has highlighted the importance of interpreting the prognostic value of pSTAT3 Y705 with the knowledge of the expression status of STAT3b.
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